The fertility drug extracted from postmenopausal women's urine that provides both hormonal signals the ovary needs to grow eggs—and why it remains the backbone of IVF protocols and male fertility treatment worldwide

Human menopausal gonadotropin occupies a foundational position in reproductive endocrinology: it is the original dual-gonadotropin preparation, providing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity in a single injection. First used in fertility medicine in the 1960s and refined into the highly purified preparation Menopur by Ferring Pharmaceuticals, HMG has been a cornerstone of IVF stimulation protocols and spermatogenesis induction for decades.

Like HCG, HMG is not a peptide. The FSH component weighs approximately 35,500 daltons and the LH-active component approximately 28,500 daltons—both are heavily glycosylated heterodimeric glycoproteins far larger than the peptides typically covered on this site. Peptidings includes HMG because it is integral to the fertility and hormonal optimization protocols that overlap with peptide use, and because understanding the gonadotropin system requires understanding all its pharmaceutical components.

The evidence base is extensive: meta-analyses of randomized trials involving thousands of patients confirm that HMG is at least as effective as recombinant FSH for IVF pregnancy rates. In men with hypogonadotropic hypogonadism, HCG-plus-HMG therapy induces spermatogenesis in more than 90% of patients. This is a standard-of-care medication with decades of pharmacovigilance data.

Quick Facts: HMG at a Glance

What Is HMG (Human Menopausal Gonadotropin)?

Pronunciation: aitch-em-jee (human menopausal gonadotropin)

The ovary needs two hormonal signals to produce a mature egg: FSH to grow the follicle and LH to provide the androgen substrate that granulosa cells convert into estrogen. This "two-cell, two-gonadotropin" model is a foundational principle of reproductive biology, and HMG is the drug that delivers both signals in a single injection.

Human menopausal gonadotropin is a mixture of FSH and LH activity extracted from the urine of postmenopausal women. After menopause, the ovaries stop producing inhibin, and the pituitary responds by increasing gonadotropin secretion—flooding the urine with FSH and residual LH-like glycoproteins. Pharmaceutical manufacturers collect this urine, purify the gonadotropins, and produce a standardized preparation for clinical use.

A note on classification: HMG is not a peptide. Both its FSH and LH/HCG components are large glycoprotein hormones—heavily glycosylated heterodimers weighing 28,500–35,500 daltons each. This is an order of magnitude larger than the peptides typically discussed on this site. Peptidings covers HMG because it is integral to the fertility medicine toolkit and because understanding the gonadotropin system is essential for anyone using hormonal peptides.

A pharmacological subtlety worth noting: in highly purified HMG (Menopur), the LH-like activity comes not from LH itself but from co-purified HCG. LH is unstable during purification and is largely removed, while the more stable HCG-like glycoprotein from postmenopausal urine is retained. Menopur is therefore functionally an FSH + HCG combination, not FSH + LH—a distinction that has subtle but real implications for receptor signaling.

Origins and Discovery

The story of HMG begins with a simple observation: postmenopausal women's urine contains large quantities of gonadotropins because, without functioning ovaries to provide feedback, the pituitary gland keeps producing FSH and LH at elevated levels.

In the late 1950s and early 1960s, reproductive endocrinologist Bruno Lunenfeld pioneered the extraction of gonadotropins from postmenopausal urine for therapeutic use. The first commercial preparation—Pergonal—became available in the 1960s and transformed fertility medicine by enabling controlled ovarian stimulation for the first time. Before HMG, women with anovulatory infertility had limited treatment options.

Early HMG preparations were crude, containing numerous urinary proteins alongside the gonadotropins. Over subsequent decades, purification technology improved dramatically. The current standard—highly purified HMG (HP-hMG, marketed as Menopur by Ferring Pharmaceuticals)—delivers consistent FSH and LH activity with minimal urinary protein contamination. HP-hMG can be administered subcutaneously rather than intramuscularly, improving patient comfort.

The development of recombinant FSH (Gonal-F, Follistim) in the 1990s created a competitor—pure FSH produced in CHO cells without urinary extraction. The debate over whether the LH activity in HMG provides clinical benefit over pure FSH has fueled dozens of clinical trials and meta-analyses, ultimately concluding that both approaches produce equivalent pregnancy rates, with HMG possibly offering advantages in embryo quality.

Mechanism of Action

The Two-Cell, Two-Gonadotropin Model

Ovarian steroidogenesis requires two cell types and two hormonal signals working in concert. Theca cells, in the outer follicular layer, respond to LH by producing androgens (androstenedione, testosterone). Granulosa cells, in the inner layer, respond to FSH by expressing aromatase, which converts those androgens into estrogens (estradiol). Neither cell type can produce estrogen alone—theca cells lack aromatase, and granulosa cells lack the enzymatic machinery to produce androgens de novo.

HMG provides both halves of this equation. The FSH component stimulates granulosa cell proliferation, aromatase expression, and follicular growth. The LH/HCG component stimulates theca cell androgen production, providing substrate for granulosa aromatization. The result is coordinated follicular development and estradiol production.

Why LH Activity Might Matter

The clinical debate around HMG versus recombinant FSH centers on whether the LH component adds value. Pure FSH stimulates follicular growth effectively, but some evidence suggests that LH-deficient stimulation produces suboptimal endometrial receptivity and lower-quality embryos. Granulosa cell gene expression studies show that HMG upregulates genes related to implantation support compared to rFSH—a potential molecular basis for the embryo quality advantage observed in some trials. PMID 20226040

In Men: Spermatogenesis Induction

For men with hypogonadotropic hypogonadism (where the pituitary fails to produce adequate FSH and LH), HMG provides the FSH signal that Sertoli cells need to support spermatogenesis. Combined with HCG (which provides the LH signal for Leydig cells), HMG completes the gonadotropin replacement needed to initiate and maintain sperm production. The standard protocol—HCG for 3–6 months to establish testosterone, then add HMG to drive spermatogenesis—induces sperm production in more than 90% of patients.

The HCG-in-HMG Nuance

In HP-hMG (Menopur), the LH-like activity comes from co-purified HCG rather than from LH itself. HCG and LH display biased agonism at the LHCGR—HCG preferentially activates cAMP signaling, while LH produces relatively more beta-arrestin signaling. This means Menopur's LH-receptor activity may have subtly different downstream effects than a preparation containing actual LH. The clinical significance of this distinction is debated.

Key Research Areas and Studies

HP-hMG vs. Recombinant FSH: The Central Debate

The most extensively studied question in HMG research is whether it performs as well as—or better than—recombinant FSH for IVF outcomes. Al-Inany and colleagues conducted a meta-analysis of five prospective RCTs involving approximately 2,000 patients and found no significant difference in ongoing pregnancy rates or live birth rates between HP-hMG (Menopur) and recombinant FSH (Gonal-F). Their conclusion: "Combined data do not support a clinical superiority of Gonal-F over Menopur." PMID 20389096

The MEGASET-HR Trial (Phase 3)

The MEGASET-HR trial specifically addressed high-responder patients—women at elevated risk of OHSS. Approximately 600 predicted high responders were randomized to HP-hMG or recombinant FSH in GnRH antagonist cycles. The primary endpoint of ongoing pregnancy rate was 35.5% for HP-hMG versus 30.7% for rFSH—noninferiority confirmed. HP-hMG was also associated with lower cost per live birth, an important consideration in a field where treatment costs are substantial. PMID: PMC8244378

Embryo Quality Advantage

Bosch and colleagues found that HP-hMG produced higher-quality embryos in IVF (but not ICSI) compared to recombinant FSH. The proposed mechanism: LH activity supports granulosa cell function and endometrial receptivity through pathways that pure FSH does not activate. This finding has been reproduced in some but not all subsequent studies—the advantage is real but modest. PMID 17640944

Spermatogenesis Induction: The Male Evidence

Rohayem and colleagues conducted a comprehensive meta-analysis of 41 studies involving 1,673 men with pathologic gonadotropin deficiency. Gonadotropin therapy (HCG combined with HMG or FSH) induced spermatogenesis in more than 90% of patients, with an average sperm concentration of 11.6 million/mL after 18 months of treatment. A subsequent RCT confirmed a 91.3% overall success rate, with upfront combination therapy (HCG + FSH from the start) achieving 100% response. PMID 39445789

HMG vs. Recombinant FSH: The Clinical Calculus

The most clinically relevant comparison in reproductive endocrinology is HMG versus recombinant FSH—a debate that has generated more randomized trials than almost any other question in fertility medicine.

What the Data Show

Meta-analyses consistently find equivalent pregnancy rates. The debate is about secondary outcomes: embryo quality, OHSS risk, oocyte yield, and cost. HMG tends to produce fewer oocytes per cycle but equivalent or higher pregnancy rates—suggesting better per-embryo quality. This "fewer but better" profile may represent a safety advantage in high responders by reducing OHSS risk while maintaining efficacy.

The Cost Question

HMG (Menopur) is generally less expensive per cycle than recombinant FSH (Gonal-F, Follistim). The MEGASET-HR trial specifically documented lower cost per live birth with HP-hMG. In a field where out-of-pocket treatment costs can exceed $15,000–$20,000 per cycle, this cost difference is clinically meaningful.

Why the Debate Persists

Recombinant FSH advocates emphasize batch-to-batch consistency and the elimination of urinary-derived protein contaminants. HMG advocates emphasize the physiological rationale for dual gonadotropin activity and the cost advantage. In practice, many reproductive endocrinologists use both—adjusting the protocol based on patient characteristics, prior response, and cost considerations.

Claims vs. Evidence

The Human Evidence Landscape

Al-Inany Meta-analysis (2010)

Design: Meta-analysis of 5 prospective RCTs. Total N~2,000. HP-hMG (Menopur) vs. recombinant FSH (Gonal-F) in IVF/ICSI.

Findings: No significant difference in ongoing pregnancy rate or live birth rate per embryo transfer. HP-hMG produced fewer oocytes but equivalent outcomes.

Limitations: Heterogeneous stimulation protocols across included trials. Quality of individual RCTs varied.

MEGASET-HR (Phase 3 RCT, 2021)

Design: Prospective, randomized, controlled. N~600 predicted high-responder patients. HP-hMG vs. rFSH in GnRH antagonist cycles.

Findings: Ongoing pregnancy rate 35.5% (HP-hMG) vs. 30.7% (rFSH)—noninferiority confirmed. Lower cost per live birth with HP-hMG.

Limitations: Industry-sponsored (Ferring). Open-label. Selected population (high responders only—generalizability to normal responders assumed but not tested in this trial).

Rohayem Spermatogenesis Meta-analysis (2024)

Design: Systematic review of 41 studies. N=1,673 men with pathologic gonadotropin deficiency treated with HCG + HMG/FSH.

Findings: Average sperm concentration after 18 months: 11.6 million/mL. Spermatogenesis achieved in >90% of patients.

Limitations: Heterogeneous study designs and patient populations. Mostly observational data. Few RCTs.

Spermatogenesis Induction RCT (2025)

Design: First RCT comparing FSH pre-treatment vs. upfront HCG + FSH in congenital hypogonadotropic hypogonadism. N=23.

Findings: Overall success rate 91.3%. Upfront combination (HCG + FSH from day 1) achieved 100% response rate.

Limitations: Very small sample size (N=23). Single-center. Novel protocol not yet replicated.

Bosch Embryo Quality RCT (2008)

Design: Randomized, controlled. N~200. HP-hMG vs. rFSH in IVF.

Findings: HP-hMG produced higher-quality embryos in IVF cycles. No difference in ICSI cycles.

Limitations: Embryo quality is a surrogate endpoint. Did not reach significance for live birth rate difference. Moderate sample size.

Safety, Risks, and Limitations

Ovarian Hyperstimulation Syndrome

OHSS risk with HMG is comparable to recombinant FSH—approximately 1–5% of IVF cycles, with severe OHSS occurring in less than 1% with modern protocols. Risk management strategies include GnRH antagonist cycles, GnRH agonist trigger (instead of HCG trigger), lower starting doses, and coasting protocols. Some evidence suggests HMG's tendency to produce fewer oocytes than rFSH may represent a passive OHSS risk reduction in high responders.

Multiple Gestation

The risk of multiple pregnancy is inherent to ovarian stimulation, not specific to HMG. In IVF, this risk is managed by single embryo transfer policies. In ovulation induction without IVF, careful monitoring with cycle cancellation if excessive follicles develop is standard.

Injection Site Reactions

Mild and transient. HP-hMG (Menopur) can be administered subcutaneously, which is generally better tolerated than intramuscular injection. Some patients report burning sensation at the injection site with Menopur—attributed to the formulation's acidity.

Long-Term Safety

HMG has been used for over 50 years. Large epidemiological studies have not demonstrated increased cancer risk (ovarian or breast) associated with gonadotropin use, though this has been a theoretical concern. The most comprehensive data come from cohort studies following IVF patients over decades.

Legal and Regulatory Status

FDA-Approved Indications

HMG (menotropins, brand name Menopur) is FDA-approved for ovulation induction in women with anovulatory infertility and for controlled ovarian stimulation in IVF/ART protocols.

Regulatory Advantage Over HCG

Unlike HCG, HMG was not reclassified under the BPCIA as a biologic. Menopur remains available through standard pharmaceutical channels and compounding pharmacies. This regulatory stability has made HMG's supply chain more predictable than HCG's since 2020.

WADA Status

HMG is prohibited at all times under WADA code S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Gonadotropins can be used to manipulate reproductive hormone levels—the basis for prohibition.

Off-Label Use in Males

HMG use for spermatogenesis induction in hypogonadotropic hypogonadism is supported by specialty guidelines (EAU, AUA) and extensive clinical evidence, though the specific FDA label does not include a male indication. This is standard-of-care off-label prescribing.

Research Protocols and Formulation Considerations

Current Formulation

Menopur (HP-hMG) is supplied as a lyophilized powder for reconstitution. Each vial contains 75 IU FSH activity and 75 IU LH activity. Reconstituted with sodium chloride 0.9% solution. Administered subcutaneously. Multiple vials can be combined for higher doses.

Storage

Lyophilized powder: store at room temperature (up to 25°C). Reconstituted solution: use immediately or within 28 days refrigerated (varies by formulation).

Pharmacokinetics

FSH component: Tmax ~12–18 hours, half-life ~37 hours. LH/HCG component: Tmax ~6–12 hours, half-life ~24 hours. The longer FSH half-life means steady-state levels are achieved within 3–4 days of daily dosing.

Dosing in Published Research

IVF/Controlled Ovarian Stimulation

Standard: 150–225 IU subcutaneous daily, starting cycle day 2–3. Continue for 8–12 days based on follicular monitoring (transvaginal ultrasound + serum estradiol). Dose adjustment: increase by 75 IU increments if follicular response is inadequate; decrease if response is excessive. Maximum recommended dose: 450 IU/day.

Ovulation Induction (Non-IVF)

Standard: 75–150 IU daily for 7–12 days, with follicular monitoring. Followed by HCG trigger (5,000–10,000 IU) when lead follicle reaches 18–20 mm. Close monitoring required to prevent multiple follicular development.

Male Hypogonadotropic Hypogonadism (Off-Label, Guideline-Supported)

Standard: Begin with HCG 1,500–2,000 IU 2–3× weekly for 3–6 months to establish intratesticular testosterone. If spermatogenesis not induced, add HMG 75–150 IU SC 3× weekly. Continue combination therapy for up to 18 months. Monitor semen analysis every 3–6 months.

Combination Stacks

Research into HMG combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining HMG with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Related Compounds: How HMG Compares

Edit

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
PT-141 (Bremelanotide)	Cyclic heptapeptide; MC3R/MC4R agonist; ~1,025 Da	Tier 1 — Approved Drug	Strong Foundation	MC4R agonism in hypothalamus → central sexual arousal pathway; 5,000-fold MC4R:MC1R selectivity (no pigmentation)	HSDD in premenopausal women (FDA-approved); off-label male sexual dysfunction	~3,000 across Phase 1–3 (RECONNECT N=1,247; BLOOM N=1,247)	FDA-approved 2019 (Vyleesi, Palatin/Amag)	Prohibited (S2, males only)	43% nausea rate; no postmenopausal efficacy (AFTERGLOW failed); SC injection only; limited long-term data
Melanotan II	Cyclic heptapeptide; non-selective melanocortin agonist; ~1,024 Da	Tier 3 — Pilot / Limited Human Data	Eyes Open	Non-selective MC1R/MC3R/MC4R/MC5R agonism → tanning (MC1R) + sexual arousal (MC4R) + appetite suppression (MC4R)	Tanning; sexual arousal; appetite suppression (all off-label/underground)	1 small Phase 2 (Wessells, N=12, erectile response); ~20 Phase 1 PK	Not approved; development abandoned ~2000	Prohibited (S2)	Non-selective → uncontrolled pigmentation, nevi darkening, unresolved melanoma risk; zero Phase 3 data; grey-market quality variable
Leuprolide	Nonapeptide; GnRH superagonist; 1,209 Da	Tier 1 — Approved Drug	Strong Foundation	GnRH-R super-agonism → initial flare (LH/T surge) → receptor desensitization → chemical castration; Kd ~0.1 nM	Prostate cancer; endometriosis; uterine fibroids; central precocious puberty	500,000+ in registries; dozens of Phase 3 RCTs; decades of pharmacovigilance	FDA-approved 1985 (Lupron, Eligard, multiple generics)	Prohibited (S2)	Hot flashes 60–70%; bone density loss 2–3%/year; mood changes; temporary symptom flare at initiation
HCG (Human Chorionic Gonadotropin)	Glycoprotein hormone (~36,700 Da); LH/CG receptor agonist	Tier 1 — Approved Drug	Strong Foundation	LHCGR agonism → Leydig cell testosterone production; oocyte maturation trigger; 6–10× more potent than LH	Ovulation induction (IVF); male hypogonadism; fertility preservation during TRT; cryptorchidism	500,000+ across decades; Cochrane reviews for IVF; multiple RCTs	FDA-approved 1967 (Pregnyl, Novarel, Ovidrel)	Prohibited (S2, males only)	OHSS risk 1–5% in IVF; removed from 503A compounding (2020 BPCIA); debunked for weight loss
HMG (Human Menopausal Gonadotropin)	Glycoprotein mixture (FSH + LH/HCG activity); urinary-derived	Tier 1 — Approved Drug	Strong Foundation	Dual FSH (follicular growth) + LH activity (theca steroidogenesis); two-cell two-gonadotropin model	Controlled ovarian stimulation (IVF); spermatogenesis induction in HH	4,500+ across meta-analyses and RCTs; equivalent to rFSH for pregnancy rates	FDA-approved (Menopur, Ferring)	Prohibited (S2)	OHSS risk comparable to rFSH; urinary-derived (batch variability); requires specialist supervision
Kisspeptin-10	Decapeptide; GPR54 (KISS1R) agonist; ~1,302 Da	Tier 2 — Clinical Trials	Reasonable Bet	GPR54 agonism on hypothalamic GnRH neurons → endogenous GnRH/LH release; master upstream regulator of HPG axis	IVF oocyte maturation trigger (OHSS-free); hypothalamic amenorrhea; HPG axis reactivation	~145 across Phase 1–2 (IVF RCT N=60; HA studies; healthy volunteers)	Not approved (investigational; Phase 2 completed)	Not explicitly listed	~4-minute half-life (KP-10); Phase 3 pending; KP-54 preferred for clinical use; no chronic dosing data
Oxytocin	Cyclic nonapeptide; OXTR agonist; 1,007 Da	Tier 1 — Approved Drug	Strong Foundation	OXTR (Gq/Gi-coupled) → uterine contraction (peripheral) + social cognition/bonding/stress modulation (central)	Labor induction/augmentation; postpartum hemorrhage; milk letdown; investigational: autism, anxiety, PTSD	500,000+ obstetric use; autism RCT N=250 (negative); psychiatric meta-analyses	FDA-approved (Pitocin; Syntocinon outside US)	Not prohibited	Uterine hyperstimulation (dose-dependent); autism RCT negative; neuropsych results inconsistent; short half-life (3–5 min IV)

↑ Back to Contents

Summary of Key Findings

HMG is a foundational reproductive endocrinology drug—the original dual-gonadotropin preparation that has been used in fertility medicine for over half a century. Its mechanism is straightforward: provide both FSH and LH activity to drive coordinated follicular development in women and spermatogenesis in men. The evidence base is large, consistent, and mature.

For IVF, meta-analyses involving thousands of patients confirm that HMG produces pregnancy rates equivalent to recombinant FSH, with possible advantages in embryo quality and definite advantages in cost. The MEGASET-HR trial confirmed noninferiority in high responders—a population where HMG's tendency to produce fewer oocytes may actually represent a safety advantage.

For male hypogonadotropic hypogonadism, gonadotropin therapy combining HCG and HMG induces spermatogenesis in more than 90% of patients—one of the highest success rates of any reproductive intervention. The protocol is well-established, guideline-supported, and has been refined over decades of clinical use.

HMG's limitations are shared with all gonadotropin therapies: OHSS risk, cost, injection burden, and the need for specialist monitoring during ovarian stimulation. These are manageable with modern protocols and do not diminish the compound's fundamental strength.

Verdict Recapitulation

HMG earns Tier 1 and a Strong Foundation verdict based on decades of FDA approval, meta-analyses confirming equivalence to recombinant FSH for IVF outcomes, a >90% spermatogenesis induction rate in hypogonadotropic men, and extensive long-term safety data. This is a standard-of-care medication with an evidence base that has only grown stronger over more than 50 years of clinical use.

For readers considering HMG, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source HMG

Further Reading and Resources

If you want to go deeper on HMG, the evidence landscape for sexual health & hormonal peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Sexual Health & Hormonal Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: HMG — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Al-Inany HG, Abou-Setta AM, Aboulghar MA, et al. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecological Endocrinology, 2009;25(6):372–378. PMID 20389096
2. Devroey P, Pellicer A, Nyboe Andersen A, et al. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer (MEGASET-HR). Human Reproduction, 2021;36(5):1423–1432. PMID: PMC8244378
3. Bosch E, Vidal C, Labarta E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists—a randomized study. Human Reproduction, 2008;23(10):2346–2351. PMID 17640944
4. Rohayem J, Nieschlag E, Kliesch S, et al. An update on the treatment of hypogonadotropic hypogonadism: gonadotropin therapy in male patients. Andrology, 2024;12(3):567–582. PMID 39445789
5. Vicari E, Grazioso C, Burrello N, et al. Epigenetic effects of gonadotropin-stimulated follicle fluid on granulosa cell gene expression. Reproductive BioMedicine Online, 2010;20(2):157–166. PMID 20226040
6. Schaison G, Dousset B. Spermatogenesis induced by human menopausal gonadotropin maintained by human chorionic gonadotropin in hypogonadotropic hypogonadism. Fertility and Sterility, 1979;31(5):505–509. PMID 362785

---